Semaglutide

GLP-1 receptor agonist peptide. A 31-amino acid sequence with a C18 fatty diacid side chain modification for extended half-life. One of the most extensively studied GLP-1 analogues in the published research literature.

98%+ purity 5mg vial HPLC tested CoA published US warehoused

$99 per vial · free shipping over $150

View Certificate of Analysis

Research purposes only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any condition. For laboratory and in vitro research use only. Must be 18+ to purchase.

About this compound

Semaglutide

Semaglutide is a GLP-1 receptor agonist with a 94% sequence homology to native GLP-1. Its distinguishing structural feature is a C18 fatty diacid chain attached via a linker, which facilitates albumin binding and substantially extends its half-life compared to earlier generation GLP-1 analogues. This structural modification has been studied extensively in the published literature as a model for long-acting peptide design.

What I noticed when reviewing the semaglutide research base was the depth and breadth of available published studies. It is one of the most thoroughly characterised GLP-1 analogues in research, which makes it a valuable reference compound for in vitro and model-based metabolic research programs.

My experience with the research literature in this space consistently shows semaglutide used as a comparator or benchmark compound in studies examining novel GLP-1 agonists. Its well-established pharmacodynamic and pharmacokinetic profile in model systems makes it useful as a reference point for researchers designing comparative protocols.

Our semaglutide is synthesised to 98%+ purity and verified by HPLC at an independent ISO/IEC 17025-accredited laboratory. Full CoA for batch #2608 is on the Lab Results page.

Receptor

GLP-1 agonist
94% homology to native GLP-1

Format

5mg lyophilised powder
Amber glass vial, rubber stopper, aluminium crimp cap

Storage

Lyophilised: -20°C, 24 months
Reconstituted: 2-8°C, 28 days. Protect from light.

Purity

98.5%
HPLC verified · Batch #2608

Research Notes

What researchers have observed

What I noticed

Semaglutide has one of the most well-documented receptor binding profiles of any GLP-1 agonist in the research literature. Its albumin-binding side chain modification is consistently cited as the mechanism behind its extended half-life compared to native GLP-1 in model systems.

Research depth

My experience reviewing metabolic peptide literature shows semaglutide frequently appearing as a reference compound in comparative studies. This makes it particularly useful for researchers who need a well-characterised baseline when studying newer or less-documented GLP-1 pathway compounds.

Synthesis note

The fatty acid side chain modification on semaglutide makes it one of the more structurally complex peptides we carry. Achieving 98%+ purity with the intact side chain requires precise synthesis control. Batch #2608 came in at 98.5% HPLC with full sequence confirmation via MS.

Pairing context

Researchers studying GLP-1 pathway mechanisms often include semaglutide alongside Retatrutide as a single vs triple agonist comparison. This pairing appears with increasing frequency in recently published metabolic research protocols.

DISCLAIMER: Semaglutide is sold by Apex Research Labs strictly for in vitro and laboratory research purposes only. It is not intended for human consumption. It is not a drug, supplement, or food product. This product has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease or medical condition. You must be 18 years of age or older to purchase. By purchasing this product, you confirm that you are a qualified researcher using this compound solely for lawful scientific research purposes and in compliance with all applicable local, state, and federal laws and regulations. Apex Research Labs assumes no liability for any misuse of this product.